Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Breast Neoplasms 311 Carcinoma, Non-Small-Cell Lung 282 Prostatic Neoplasms 160 Colorectal Neoplasms 155 Carcinoma, Hepatocellular 144 Neoplasms 134 Leukemia, Myeloid, Acute 132 Lung Neoplasms 115 Squamous Cell Carcinoma of Head and Neck 108 Triple Negative Breast Neoplasms 102 Multiple Myeloma 102 Recurrence 99 Pancreatic Neoplasms 94 Stomach Neoplasms 93 Ovarian Neoplasms 87 Neoplasm Metastasis 87 Lymphoma, Large B-Cell, Diffuse 81 Sarcoma 70 Precursor Cell Lymphoblastic Leukemia-Lymphoma 68 Esophageal Neoplasms 67 Uterine Cervical Neoplasms 66 Melanoma 65 Brain Neoplasms 65 Rectal Neoplasms 62 Head and Neck Neoplasms 62 Glioblastoma 60 Carcinoma, Renal Cell 57 Lymphoma 55 Myelodysplastic Syndromes 54 Esophageal Squamous Cell Carcinoma 54

Interventions

trametinib 1 dabrafenib 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recruiting × Rare Malignant Neoplasm × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡